Applied DNA Customer ÚHKT Initiates Phase I Clinical Trial for Rapidly Manufacturable CAR T-Cell Therapy Produced from Linea DNA [Yahoo! Finance]
Applied DNA Sciences, Inc. (APDN)
Last applied dna sciences, inc. earnings: 8/10 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
adnas.com/molecular-based-security/investors
Company Research
Source: Yahoo! Finance
Linea DNA is an enzymatically produced, linear DNA manufactured by Applied DNA's proprietary, large-scale polymerase chain reaction (PCR) based manufacturing platform, the Linea DNA platform. Was this helpful? Yes No What is the expected outcome of the UHKT-CAR123 clinical trial? The trial aims to address the high rate of treatment failure in AML patients by leveraging advancements in genetic medicines, such as CAR T-cell therapies, to potentially improve patient outcomes. Was this helpful? Yes No What is the recent development in the treatment of relapsed and/or refractory acute myeloid leukemia (AML)? The State Institute for Drug Control of the Czech Republic (SÚKL) has approved an application for a Phase I clinical trial of an investigational CD123-specific autologous CAR T-cell therapy by the Institute of Hematology and Blood Transfusion (ÚHKT) in Prague, which utilizes Applied DNA's synthetic DNA, Linea DNA, as a critical component in its manufacture. Was t
Show less
Read more
Impact Snapshot
Event Time:
APDN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
APDN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
APDN alerts
High impacting Applied DNA Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
APDN
News
- Applied DNA Customer ÚHKT Initiates Phase I Clinical Trial for Rapidly Manufacturable CAR T-Cell Therapy Produced from Linea DNA Accesswire
- Applied DNA Sciences (APDN) Reports Q4 Loss, Tops Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- Applied DNA Announces Fourth Quarter and Fiscal Year 2024 Financial Results, Announces Strategic Restructuring to Prioritize the Manufacture of Critical Starting Materials for Genetic Medicines [Yahoo! Finance]Yahoo! Finance
- Applied DNA Announces Fourth Quarter and Fiscal Year 2024 Financial Results, Announces Strategic Restructuring to Prioritize the Manufacture of Critical Starting Materials for Genetic Medicines Accesswire
- Applied DNA to Report Fourth Quarter and Fiscal Year 2024 Financial Results After Market Close on December 17, 2024; Sets Webcast and Conference Call for January 9, 2025, to Coincide with Update on GMP Manufacturing Facility Build-out [Yahoo! Finance]Yahoo! Finance
APDN
Earnings
- 12/17/24 - Beat
APDN
Sec Filings
- 12/17/24 - Form 10-K
- 12/17/24 - Form 8-K
- 12/10/24 - Form DEFA14A
- APDN's page on the SEC website